ARTICLE | Company News
Protiva, Merck deal
October 22, 2007 7:00 AM UTC
MRK received a non-exclusive, worldwide license to Protiva's stable nucleic acid lipid particles (SNALP) delivery technology for use with RNAi therapeutics. Protiva will receive an undisclosed one-tim...